Clinical Trial Update: Engineered Dendritic Cell Vaccines for Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating an engineered dendritic cell vaccine for multiple myeloma; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasmacytoma

Drugs mentioned

• Engineered dendritic cell vaccine (Engineered dendritic cell vaccine)

Snippet

Sponsor: Shenzhen Geno-Immune Medical Institute | Conditions: Multiple Myeloma or Plasmacytoma | Phase 1 | Status: RECRUITING